Stage IIB Cervical Cancer Clinical Trial
Official title:
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 (MK-1775) in Combination With Cisplatin and Radiation in Cervical Cancer (10041848, 10008224, 10008328)
This phase I trial studies the side effects and best dose of WEE1 inhibitor MK-1775 (AZD1775) when given together with cisplatin and radiation therapy in treating patients with cervical cancer. WEE1 inhibitor MK-1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells. Giving WEE1 inhibitor MK-1775 together with cisplatin and radiation therapy may be a better treatment for patients with cervical cancer.
PRIMARY OBJECTIVES:
I. To determine the recommended phase II dose (RP2D) and safety profile of AZD1775 (MK-1775)
in combination with cisplatin and radiation in patients with cervical cancer (phase I).
SECONDARY OBJECTIVES:
I. To evaluate the pharmacodynamic effects of AZD1775 (MK-1775) drugs when administered in
combination with cisplatin and radiation (in particular, for the 15 patients treated in an
expansion cohort at the RP2D). Pharmacodynamic biomarkers will include: phosphorylated cell
division cycle protein 2 homolog (pCDC2), antigen Ki-67 (Ki67), gamma H2A histone family,
member X (gH2AX), phosphorylated (phospho)-histone 3 (pH3), and cleaved caspase-3 (CC3).
II. To obtain preliminary information about the progression-free survival of AZD1775
(MK-1775) in combination with standard radiation and chemotherapy in women with locally
advanced high-risk cervix cancer.
III. To determine the acute and late toxicity of AZD1775 (MK-1775) when administered to
patients with cervix cancer in combination with standard radiation and concurrent
chemotherapy.
IV. To correlate the serum pharmacokinetic parameters—maximum concentration (Cmax), time to
peak concentration (Tmax), 8-hours concentration (C8), and area under the curve (AUC)
(0-8)—with the drug concentration in the tumor tissue (for patients in the expansion cohort).
OUTLINE: This is a dose-escalation study of WEE1 inhibitor MK-1775. Patients are assigned to
1 of 3 treatment groups.
COHORT I: Patients receive WEE1 inhibitor MK-177 orally (PO) twice daily (BID) on days 1-2,
8-9, 15-16, 22-23, and 29-30.
COHORT II: Patients receive WEE1 inhibitor MK-177 PO BID on days 4-5, 11-12, 18-19, 25-26,
and 32-33 or on days 3-5, 10-12, 17-19, 24-26, and 31-33.
COHORT III: Patients receive WEE1 inhibitor MK-177 PO BID on days 1-5, 8-12, 15-19, 22-26,
and 29-33.
In all cohorts, patients also receive cisplatin intravenously (IV) over 1 hour on days 1, 8,
15, 22, and 29 and undergo of pelvic external beam radiation therapy 5 days a week for 5
weeks followed by pulsed-dose rate or high-dose rate brachytherapy 5 days a week in weeks
6-8.
After completion of study treatment, patients are followed up at 4 weeks, at 3, 6, and 12
months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00054444 -
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
Phase 1 | |
Completed |
NCT00416455 -
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01764802 -
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
|
Phase 2 | |
Completed |
NCT00068549 -
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
Phase 1 | |
Completed |
NCT00559377 -
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT03469531 -
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
|
Phase 2 | |
Completed |
NCT00897442 -
Collecting Tumor Samples From Patients With Gynecological Tumors
|
N/A | |
Completed |
NCT01098630 -
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
|
||
Completed |
NCT00941070 -
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
|
Phase 2 | |
Withdrawn |
NCT01019278 -
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
|
Phase 2 | |
Completed |
NCT00104910 -
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
|
Phase 1 | |
Terminated |
NCT00262821 -
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
|
Phase 3 | |
Completed |
NCT00107445 -
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
|
Phase 2 | |
Terminated |
NCT01992861 -
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
|
||
Terminated |
NCT00577317 -
Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer
|
Phase 3 | |
Completed |
NCT00017004 -
Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia
|
Phase 3 | |
Completed |
NCT03198286 -
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT01835171 -
Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
|
Phase 2 | |
Completed |
NCT00460356 -
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes
|
N/A |